Conexeu Sciences (NASDAQ:CNXU) Coverage Initiated by Analysts at HC Wainwright

Stock analysts at HC Wainwright started coverage on shares of Conexeu Sciences (NASDAQ:CNXU) in a research report issued on Monday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $20.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 50.60% from the stock’s previous close.

Separately, Wall Street Zen upgraded Conexeu Sciences to a “hold” rating in a report on Saturday, May 30th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $20.00.

Conexeu Sciences Price Performance

Shares of NASDAQ CNXU opened at $13.28 on Monday. Conexeu Sciences has a one year low of $9.60 and a one year high of $18.79.

Conexeu Sciences Company Profile

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.